Literature DB >> 1714524

Localization of immunogenic domains in the human immunodeficiency virus type 2 envelope.

M L Huang1, M Essex, T H Lee.   

Abstract

Highly immunogenic domains have not yet been defined in the extracellular protein of the human immunodefiency virus type 2 (HIV-2) envelope. In this study, six contiguous segments covering the entire HIV-2ST envelope were amplified and cloned into a bacterial expression vector to localize the relative immunogenic reactivity of different regions of the molecule by Western blot (immunoblot) analysis. Our results demonstrate that the extracellular protein of the HIV-2 envelope contains highly immunogenic epitopes with potential value as type-specific markers for HIV-2 infection.

Entities:  

Keywords:  Africa; Africa South Of The Sahara; Americas; Biology; Developed Countries; Developing Countries; Diseases; Examinations And Diagnoses; French Speaking Africa; Hematologic Tests; Hiv Infections; Immunity; Immunologic Factors; Laboratory Examinations And Diagnoses; Laboratory Procedures; Massachusetts; Membrane Proteins; North America; Northern America; Physiology; Senegal; United States; Viral Diseases; Western Africa

Mesh：

Substances：

Year:  1991        PMID： 1714524      PMCID： PMC248972     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  47 in total

1.  Isolation of ras GTP-binding mutants using an in situ colony-binding assay.

Authors:  L A Feig; B T Pan; T M Roberts; G M Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

2.  Envelope cross-reactivity between human immunodeficiency virus types 1 and 2 detected by different serological methods: correlation between cross-neutralization and reactivity against the main neutralizing site.

Authors:  B Böttiger; A Karlsson; P A Andreasson; A Nauclér; C M Costa; E Norrby; G Biberfeld
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

3.  Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia.

Authors:  R K Saiki; S Scharf; F Faloona; K B Mullis; G T Horn; H A Erlich; N Arnheim
Journal:  Science       Date:  1985-12-20       Impact factor: 47.728

4.  Persistent infection of rhesus macaques with a molecular clone of human immunodeficiency virus type 2: evidence of minimal genetic drift and low pathogenetic effects.

Authors:  G Franchini; P Markham; E Gard; K Fargnoli; S Keubaruwa; L Jagodzinski; M Robert-Guroff; P Lusso; G Ford; F Wong-Staal
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

5.  Discrimination of HIV-2 infection from HIV-1 infection by western blot and radioimmunoprecipitation analysis.

Authors:  T J Holzer; R G Allen; C A Heynen; M M Kennedy; M F Knigge; D A Paul; G J Dawson
Journal:  AIDS Res Hum Retroviruses       Date:  1990-04       Impact factor: 2.205

Review 6.  HIV-2 link to AIDS in West Africa.

Authors:  I Romieu; R Marlink; P Kanki; S M'Boup; M Essex
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

7.  Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant.

Authors:  G J LaRosa; J P Davide; K Weinhold; J A Waterbury; A T Profy; J A Lewis; A J Langlois; G R Dreesman; R N Boswell; P Shadduck
Journal:  Science       Date:  1990-08-24       Impact factor: 47.728

8.  Serological evidence for virus related to simian T-lymphotropic retrovirus III in residents of west Africa.

Authors:  F Barin; S M'Boup; F Denis; P Kanki; J S Allan; T H Lee; M Essex
Journal:  Lancet       Date:  1985 Dec 21-28       Impact factor: 79.321

9.  Clinical experience of AIDS in relation to HIV-1 and HIV-2 infection in a rural hospital in Ivory Coast, West Africa.

Authors:  M Gody; S A Ouattara; G de Thé
Journal:  AIDS       Date:  1988-12       Impact factor: 4.177

10.  Extensive variation of human immunodeficiency virus type-1 in vivo.

Authors:  M S Saag; B H Hahn; J Gibbons; Y Li; E S Parks; W P Parks; G M Shaw
Journal:  Nature       Date:  1988-08-04       Impact factor: 49.962
View more
  5 in total

1.  Use of a new dual-antigen enzyme-linked immunosorbent assay to detect and characterize the human antibody response to the human immunodeficiency virus type 2 envelope gp125 and gp36 glycoproteins.

Authors:  José Maria Marcelino; Helena Barroso; Fátima Gonçalves; Sofia Marques Silva; Carlos Novo; Perpétua Gomes; Ricardo Camacho; Nuno Taveira
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

2.  Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodies.

Authors:  L Luo; Y Li; P M Cannon; S Kim; C Y Kang
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

3.  Evolutionary and structural features of the C2, V3 and C3 envelope regions underlying the differences in HIV-1 and HIV-2 biology and infection.

Authors:  Helena Barroso; Pedro Borrego; Inês Bártolo; José Maria Marcelino; Carlos Família; Alexandre Quintas; Nuno Taveira
Journal:  PLoS One       Date:  2011-01-20       Impact factor: 3.240

4.  HIV-1 envelope glycoproteins isolated from Viremic Non-Progressor individuals are fully functional and cytopathic.

Authors:  Romina Cabrera-Rodríguez; Veronique Hebmann; Silvia Marfil; María Pernas; Sara Marrero-Hernández; Cecilia Cabrera; Victor Urrea; Concepción Casado; Isabel Olivares; Daniel Márquez-Arce; Silvia Pérez-Yanes; Judith Estévez-Herrera; Bonaventura Clotet; Lucile Espert; Cecilio López-Galíndez; Martine Biard-Piechaczyk; Agustín Valenzuela-Fernández; Julià Blanco
Journal:  Sci Rep       Date:  2019-04-03       Impact factor: 4.379

5.  Low Postseroconversion CD4+ T-cell Level Is Associated with Faster Disease Progression and Higher Viral Evolutionary Rate in HIV-2 Infection.

Authors:  Joakim Esbjörnsson; Patrik Medstrand; Angelica A Palm; Philippe Lemey; Marianne Jansson; Fredrik Månsson; Anders Kvist; Zsófia Szojka; Antonio Biague; Zacarias José da Silva; Sarah L Rowland-Jones; Hans Norrgren
Journal:  mBio       Date:  2019-01-08       Impact factor: 7.867
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.